Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature
暂无分享,去创建一个
Rolf A. Brekken | P. Grayburn | J. Fleming | R. Brekken | Paul A. Grayburn | Jason B. Fleming | Grzegorz Korpanty | Juliet G. Carbon | J. Carbon | G. Korpanty
[1] E. Vokes,et al. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Ellis,et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. , 2001, Cancer biotherapy & radiopharmaceuticals.
[3] M. Tabata,et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] S. Post,et al. High Expression of Vascular Endothelial Growth Factor Predicts Early Recurrence and Poor Prognosis after Curative Resection for Ductal Adenocarcinoma of the Pancreas , 2002, Pancreas.
[5] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Klibanov,et al. Targeted delivery of gas-filled microspheres, contrast agents for ultrasound imaging. , 1999, Advanced drug delivery reviews.
[7] Napoleone Ferrara,et al. Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.
[8] L. Ellis,et al. Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice , 2002, International journal of cancer.
[9] A. Jemal,et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival , 2004, Cancer.
[10] Lei Xu,et al. Pancreas Microenvironment Promotes VEGF Expression and Tumor Growth: Novel Window Models for Pancreatic Tumor Angiogenesis and Microcirculation , 2001, Laboratory Investigation.
[11] G. McBride. Researchers optimistic about targeted drugs for pancreatic cancer. , 2004, Journal of the National Cancer Institute.
[12] William R Wagner,et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. , 2005, Cancer research.
[13] J. Fleming,et al. Selective Blockade of Vascular Endothelial Growth Factor Receptor 2 With an Antibody Against Tumor-Derived Vascular Endothelial Growth Factor Controls the Growth of Human Pancreatic Adenocarcinoma Xenografts , 2006, Annals of Surgical Oncology.
[14] M. Korc,et al. Concomitant over‐expression of vascular endothelial growth factor and its receptors in pancreatic cancer , 2000, International journal of cancer.
[15] P. Dayton,et al. Targeted imaging using ultrasound contrast agents , 2004, IEEE Engineering in Medicine and Biology Magazine.
[16] J. Minna,et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.
[17] Jonathan R. Lindner,et al. Noninvasive Assessment of Angiogenesis by Ultrasound and Microbubbles Targeted to &agr;v-Integrins , 2003, Circulation.
[18] P. Choyke,et al. Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.
[19] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[20] S. Ran,et al. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. , 2003, Neoplasia.
[21] Susannah H Bloch,et al. Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. , 2004, IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society.
[22] I. Otterness,et al. Reversal of colchicine-induced mitotic arrest in Chinese hamster cells with a colchicine-specific monoclonal antibody. , 1990, The American journal of pathology.
[23] A. Harris,et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. , 2000, Cancer research.
[24] M. Korc,et al. Pancreatic cancer cell‐derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo , 2001, International journal of cancer.
[25] R. Shohet,et al. Targeting vascular endothelium with avidin microbubbles. , 2005, Ultrasound in medicine & biology.
[26] Shant Kumar,et al. CD105 is important for angiogenesis: evidence and potential applications , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] R. Brekken,et al. Vascular endothelial growth factor as a marker of tumor endothelium. , 1998, Cancer research.
[28] P. Sidhu,et al. New directions in ultrasound: microbubble contrast. , 2006, The British journal of radiology.
[29] H M Rosenberg,et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. , 2001, Journal of the National Cancer Institute.
[30] E. Butcher,et al. Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-beta ligand. , 1994, Gene.
[31] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[32] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[33] D. Fukumura,et al. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] Jonathan R. Lindner,et al. Microbubbles in medical imaging: current applications and future directions , 2004, Nature Reviews Drug Discovery.
[35] Napoleone Ferrara,et al. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. , 2005, Biochemical and biophysical research communications.
[36] S. Kumar,et al. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis , 2003, British Journal of Cancer.
[37] Wei Zhang,et al. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model , 2004, Angiogenesis.
[38] R. Brekken,et al. Combination of a monoclonal anti‐phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice , 2006, International journal of cancer.
[39] R. Stupp,et al. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. , 2003, Current molecular medicine.